| Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Y Liu, JP Bewersdorf, M Stahl, AM Zeidan Blood Reviews, 2018 | 112 | 2018 |
| Epigenetic therapy combinations in acute myeloid leukemia: what are the options? JP Bewersdorf, R Shallis, M Stahl, AM Zeidan Therapeutic advances in hematology 10, 2040620718816698, 2019 | 96 | 2019 |
| Calcium influx through plasma-membrane nanoruptures drives axon degeneration in a model of multiple sclerosis ME Witte, AM Schumacher, CF Mahler, JP Bewersdorf, J Lehmitz, ... Neuron 101 (4), 615-624. e5, 2019 | 84 | 2019 |
| Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review … JP Bewersdorf, S Giri, R Wang, RT Williams, MS Tallman, AM Zeidan, ... Haematologica 105 (11), 2659, 2020 | 82 | 2020 |
| A review of FLT3 inhibitors in acute myeloid leukemia JC Zhao, S Agarwal, H Ahmad, K Amin, JP Bewersdorf, AM Zeidan Blood reviews 52, 100905, 2022 | 79 | 2022 |
| Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts AM Zeidan, PC Boddu, MM Patnaik, JP Bewersdorf, M Stahl, RK Rampal, ... The Lancet Haematology 7 (8), e601-e612, 2020 | 76 | 2020 |
| Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States AM Zeidan, R Wang, X Wang, RM Shallis, NA Podoltsev, JP Bewersdorf, ... Blood advances 4 (10), 2192-2201, 2020 | 73 | 2020 |
| Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short-and long-term clinical outcomes: a large, retrospective … M Stahl, RM Shallis, W Wei, P Montesinos, E Lengline, J Neukirchen, ... Leukemia 34 (12), 3149-3160, 2020 | 68 | 2020 |
| Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments? JP Bewersdorf, AM Zeidan Cells 9 (10), 2310, 2020 | 65 | 2020 |
| Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes JP Bewersdorf, AM Zeidan Leukemia 33 (6), 1303-1312, 2019 | 61 | 2019 |
| Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes AM Zeidan, DJ DeAngelo, J Palmer, CS Seet, MS Tallman, X Wei, ... Annals of hematology 101 (3), 557-569, 2022 | 58 | 2022 |
| Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis JP Bewersdorf, S Giri, R Wang, N Podoltsev, RT Williams, MS Tallman, ... Leukemia 35 (6), 1643-1660, 2021 | 41 | 2021 |
| Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States AM Zeidan, NA Podoltsev, X Wang, C Zhang, JP Bewersdorf, RM Shallis, ... Blood Advances 4 (8), 1615-1623, 2020 | 40 | 2020 |
| Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis M Stahl, JP Bewersdorf, S Giri, R Wang, AM Zeidan Haematologica 105 (1), 102, 2020 | 40 | 2020 |
| Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes AM Zeidan, U Platzbecker, JP Bewersdorf, M Stahl, L Adès, U Borate, ... Blood, The Journal of the American Society of Hematology 141 (17), 2047-2061, 2023 | 39 | 2023 |
| Beyond ruxolitinib: fedratinib and other emergent treatment options for myelofibrosis JP Bewersdorf, SM Jaszczur, S Afifi, JC Zhao, AM Zeidan Cancer Management and Research, 10777-10790, 2019 | 38 | 2019 |
| Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells K North, S Benbarche, B Liu, J Pangallo, S Chen, M Stahl, JP Bewersdorf, ... Nature biotechnology 40 (7), 1103-1113, 2022 | 36 | 2022 |
| BiTEs, DARTS, BiKEs and TriKEs—are antibody based therapies changing the future treatment of AML? C Allen, AM Zeidan, JP Bewersdorf Life 11 (6), 465, 2021 | 36 | 2021 |
| Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis JP Bewersdorf, S Giri, MS Tallman, AM Zeidan, M Stahl Transfusion 60 (10), 2360-2369, 2020 | 36 | 2020 |
| The SPEED (sepsis patient evaluation in the emergency department) score: a risk stratification and outcome prediction tool JP Bewersdorf, O Hautmann, D Kofink, AA Khalil, IZ Abidin, A Loch European Journal of Emergency Medicine 24 (3), 170-175, 2017 | 36 | 2017 |
Amer Zeidan, MBBS, MHSAssociate Professor of Medicine, Yale UniversityVerified email at yale.edu
